Europe — EMA
Ondansetron Eg (Ondansetron Hydrochloride Dihydrate)
GNH USA supplies Ondansetron Eg (Ondansetron), a serotonin 5-HT3 receptor antagonist for prevention of chemotherapy, postoperative and radiotherapy‑induced
Request sourcing
What is Ondansetron Hydrochloride Dihydrate?
Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Eg, is a serotonin 5-HT3 receptor antagonist presented as an oral dosage form for oral use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiotherapy in adult patients.
GNH USA supplies Ondansetron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Ondansetron Hydrochloride Dihydrate used for?
Ondansetron Eg is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.
- Chemotherapy‑induced nausea and vomiting: prevents or reduces nausea and vomiting caused by cancer chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting associated with radiation treatment.
What are the side effects of Ondansetron Hydrochloride Dihydrate?
Ondansetron may cause a range of adverse reactions, most of which are mild and transient.
Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak.
Serious or Rare Side Effects: - QT prolongation: potential heart rhythm disturbance that may lead to arrhythmia. - Severe allergic reaction (anaphylaxis): rapid onset of swelling, rash, and breathing difficulty. - Serotonin syndrome: rare condition with agitation, hyperthermia, and muscle rigidity.
What precautions apply to Ondansetron Hydrochloride Dihydrate?
Before prescribing Ondansetron Eg, clinicians should consider several safety aspects.
- Cardiac assessment: evaluate history of arrhythmias or prolonged QT interval. - Electrolyte monitoring: correct hypokalemia, hypomagnesemia, or hypocalcemia which can exacerbate QT prolongation. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant QT‑prolonging drugs: avoid or monitor closely when combined with other agents that affect cardiac repolarization. - Dose adjustment: consider renal or hepatic function when determining dose. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.
What does Ondansetron Hydrochloride Dihydrate interact with?
Ondansetron Eg can interact with several medicines, requiring attention to avoid adverse outcomes.
Major Interactions (Avoid): - Apomorphine: co‑administration may cause severe hypotension and loss of consciousness. - Other 5‑HT3 antagonists: concurrent use provides no added benefit and may increase toxicity. - QT‑prolonging agents (e.g., quinidine, amiodarone): may significantly increase risk of cardiac arrhythmias.
Moderate Interactions (Monitor Closely): - Anticholinergics: may reduce the anti‑emetic efficacy of ondansetron. - Corticosteroids: can enhance the anti‑emetic effect, requiring dose review. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower ondansetron concentrations and reduce effectiveness.



